3 assets in Malignant Sertoli Cell Tumor

Therapeutic assets addressing Malignant Sertoli Cell Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Malignant Sertoli Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Malignant Sertoli Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Malignant Sertoli Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)